AstraZeneca (LON:AZN) Receives Overweight Rating from Barclays

AstraZeneca (LON:AZN)‘s stock had its “overweight” rating reiterated by investment analysts at Barclays in a research note issued to investors on Monday, Marketbeat Ratings reports. They presently have a £125 ($158.21) target price on the biopharmaceutical company’s stock. Barclays‘s price target points to a potential upside of 16.74% from the stock’s previous close.

A number of other equities analysts have also weighed in on the company. BMO Capital Markets restated an “outperform” rating on shares of AstraZeneca in a research note on Monday, February 12th. UBS Group decreased their target price on AstraZeneca from £107 ($135.43) to GBX 9,900 ($125.30) and set a “sell” rating on the stock in a research note on Monday, February 12th. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research note on Friday, April 5th. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research note on Thursday, April 4th. Finally, Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of AstraZeneca in a research note on Tuesday, March 12th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of £115.88 ($146.66).

AstraZeneca Price Performance

Shares of LON AZN opened at £107.08 ($135.53) on Monday. The firm has a market capitalization of £165.97 billion, a P/E ratio of 3,545.70, a P/E/G ratio of 0.87 and a beta of 0.17. The company has a quick ratio of 0.59, a current ratio of 0.82 and a debt-to-equity ratio of 75.70. The stock’s 50-day simple moving average is £102.92 and its two-hundred day simple moving average is £104.29. AstraZeneca has a twelve month low of GBX 105.92 ($1.34) and a twelve month high of £123.92 ($156.84).

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.